Product image of Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide) supplied by GNH India

Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo

Active Ingredient:
Olmesartan Medoxomil, Hydrochlorothiazide
Origin:
EU

Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, and is indicated for adults. GNH India supplies Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Olmesartan Medoxomilo + Hidroclorotiazida Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Generis Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan medoxil, combined with hydrochlorothiazide, is used in cardiovascular therapy to control blood pressure.

  • Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
  • Heart failure adjunct: assists in fluid management when used with other heart‑failure therapies.
  • Diabetic nephropathy risk reduction: helps delay progression of kidney damage associated with diabetes by controlling hypertension.
  • Stroke prevention: contributes to reduced risk of stroke in patients with high blood pressure.
  • Chronic kidney disease support: aids in blood‑pressure control for patients with mild to moderate chronic kidney disease.

How It Works

  • Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering blood pressure. The combined actions result in reduced peripheral resistance and plasma volume, leading to sustained antihypertensive effects.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Dizziness or light‑headedness
  • Headache
  • Fatigue
  • Increased urination
  • Electrolyte disturbances (e.g., low potassium)
  • Mild gastrointestinal discomfort

Serious or Rare Side Effects

  • Severe hypotension
  • Acute kidney injury
  • Hyperkalemia or severe electrolyte imbalance
  • Angio‑edema involving face, lips or airway
  • Liver function abnormalities
  • Blood cell disorders such as neutropenia

Precautions & Warnings

When prescribing Olmesartan Medoxomilo + Hidroclorotiazida, clinicians should consider several safety aspects.

  • Renal function: assess baseline creatinine and monitor periodically.
  • Electrolyte balance: check serum potassium and sodium levels regularly.
  • Pregnancy: contraindicated in the second and third trimesters; avoid use.
  • Concomitant drugs: review for potential interactions that affect potassium or renal function.
  • Hypersensitivity: discontinue if angio‑edema or severe rash develops.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan Medoxomilo + Hidroclorotiazida may interact with several medicines, requiring clinical awareness.

Major Interactions (Avoid)

  • Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
  • Aliskiren (in diabetic patients): increased risk of renal impairment and hypotension.
  • NSAIDs (high‑dose or chronic use): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

  • Lithium: possible increase in lithium levels.
  • Antidiabetic agents: enhanced glucose‑lowering effect, monitor blood sugar.
  • Other antihypertensives: additive blood‑pressure lowering, watch for hypotension.

Frequently Asked Questions

Olmesartan Medoxomilo + Hidroclorotiazida is a fixed‑dose combination of an angiotensin II receptor blocker and a thiazide diuretic. It is prescribed to lower high blood pressure in adults, often when monotherapy does not achieve target levels. Controlling hypertension helps reduce the risk of cardiovascular events such as stroke and heart attack.

Olmesartan medoxil blocks the AT1 receptor for angiotensin II, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, increasing urine output. Together they lower peripheral resistance and plasma volume, producing an additive antihypertensive effect.

The dosage of Olmesartan Medoxomilo + Hidroclorotiazida is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. The prescriber determines the appropriate strength and frequency according to clinical guidelines.

Olmesartan Medoxomilo + Hidroclorotiazida is contraindicated in the second and third trimesters of pregnancy because of potential fetal toxicity. Use during the first trimester should be avoided unless clearly needed. Limited data are available for breastfeeding; therefore, it is generally not recommended without medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent ARBs or ACE inhibitors, the Olmesartan‑hydrochlorothiazide combo offers an added diuretic effect, often achieving target blood pressure more rapidly. It may be preferred when patients need both vasodilation and volume reduction, reducing the need for multiple separate pills.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, angio‑edema and liver function abnormalities. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or marked changes in urine output.

Individuals with known hypersensitivity to olmesartan, hydrochlorothiazide or any component of the formulation should avoid it. It is also contraindicated in patients with severe renal impairment, hyperkalemia, or those who are pregnant in the second or third trimester.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT